Journal of Clinical Medicine
February 15, 2022
Lourdes Poyatos, A Acuna Torres, Esther Papaseit et al.
26 citations
Introduction and objective: Assessing the abuse potential of new substances with central nervous system activity is essential for preventing possible risks of misuse and addiction. The same methodology is recommended for the evaluation of the abuse potential of recreational drugs. This systematic review aims to assess the pharmacological effects related to the abuse potential and...
Journal of Xenobiotics
February 7, 2022
Maurizio Coppola, Francesco Bevione, Raffaella Mondola
29 citations
Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...
Cureus
February 5, 2022
Shawn Ziff, Benjamin Stern, Gregory D. Lewis et al.
32 citations
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A...
Frontiers in Psychiatry
January 21, 2022
Melina Wiedmann, Sören Kuitunen-Paul, Lukas A Basedow et al.
5 citations
ObjectivesBoth substance use, on the one hand, and the first signs of psychosis, on the other, commonly begin in adolescence. Adolescents with substance use disorder (SUD) frequently show recreational use of cannabis and 3,4-methylenedioxymethamphetamine (MDMA). When attenuated psychotic symptoms (APS) occur during the course of SUD, they are commonly attributed to the cannabis use, neglecting...
Psychological Medicine
2022
Wayne Hall
Advocates of the therapeutic use of psychedelic drugs have argued that a promising approach to treatment was prematurely abandoned in the 1960s primarily because of Richard Nixon's 'War on Drugs'.This paper (1) briefly describes research in the 1950s and 1960s in North America on the use of LSD to treat alcohol dependence, anxiety in terminal illness, and anxiety and depression; and (2)...
Addiction
2022
Thomas Knuijver, Arnt Schellekens, Maarten Belgers et al.
49 citations
Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as well as other safety concerns. This study aimed to evaluate the cardiac, cerebellar and psychomimetic safety of ibogaine...
Frontiers in Psychiatry
December 23, 2021
A. Fiorentini, Filippo Cantù, Camilla Crisanti et al.
123 citations
Background: On the current psychopharmacological panorama, the variety of substances able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic episodes are classified according to the major category of symptoms: positive, negative, or cognitive psychotic episodes. On one hand, the abuse of methamphetamines, cannabis, and cocaine plays a big role in increasing the...
Current Topics in Medicinal Chemistry
December 2, 2021
Teresa Reynolds de Sousa, João Rema, Sérgio Machado et al.
7 citations
Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects. Objective: This work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric disorders. Discussion:...
Alcoholism & Drug Abuse Weekly
November 19, 2021
Gary Enos
With nicotine being one of the most addictive substances and the available treatments for nicotine addiction leading to no better than a 30% success rate, it's no wonder that a newly announced multisite study of the psychedelic psilocybin for smoking cessation is generating excitement. While taking care not to oversell the potential of this strategy, those involved with the research hope at...
Science Advances
November 17, 2021
Marcus W. Meinhardt, Simone Pfarr, Grégory Fouquet et al.
92 citations
Alcohol-induced mGluR2 deficits are restored by psilocybin, resulting in a rescue of pathological behaviors in alcoholism.